Original Research Article

Study of coagulation disorder following haemotoxic snake envenomation in a tertiary care centre

Mubarak R.1*, B. N. Mohapatra2

1Department of Medicine, AIIMS Bhopal, Madhya Pradesh, India
2Department of Medicine, SCB Medical College, Cuttack, Odisha, India

Received: 07 April 2021
Revised: 09 May 2021
Accepted: 10 May 2021

*Correspondence:
Dr. Mubarak R.,
E-mail: mubarakr56@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Coagulopathy is the most common manifestation in cases of haemotoxic snake bites. The most common coagulopathy associated with snake envenoming worldwide is venom-induced consumption coagulopathy (VICC). The existence of overlapping clinical syndromes of VICC and thrombotic microangiopathy (TMA) in snake envenoming is the likely reason for the mistaken idea that snake bite causes disseminated intravascular coagulation (DIC). This study aims to look into the exact type coagulopathy in haemotoxic snake envenomation.

Methods: Prospective observational study was conducted from January 2017 to January 2018 at a tertiary care centre in Odisha.

Results: Out of 54, 23 (42.6%) cases were having DIC and 31 (57.4%) cases were not confirmed to be having DIC. In DIC group there was significantly delayed hospitalization (46.3±28.5 hours) when compared to group B (13.5±11.1 hours, p<0.05). Mean anti-snake venom (ASV) requirement in DIC group was significantly higher (28.3±14) than in those DIC is not confirmed (11.13±3.1, p<0.05). 21.7% cases in DIC group had kdigo stage III AKI compared to 3.3% cases of group B. 13% cases of DIC group required hemodialysis when compared to 3.2% cases of group B.

Conclusions: Early hospitalisation (preferably <12 hours and not >24 hours), early ASV administration are important to prevent full blown DIC and more serious complications. Most of the non DIC cases appears to be DIC in evolution but not confirmed to diagnosis by DIC scoring system as they reached hospital early before the development of frank DIC. TMA has not been found in this study. However further studies are needed to ascertain the exact cause of coagulopathy in non DIC group.

Keywords: Snakebite, DIC, TMA, AKI, ASV

INTRODUCTION

India is inhabited by more than 60 species of venomous snakes. Some of the most common found in India are spectacled cobra (Naja naja), common krait (Bungarus caeruleus), saw scaled viper (Echis carinatus) and Russell’s viper (Daboia russelii).1,18,25 India is estimated to have the highest snake bite mortality in the world. In a recently published study 0.47% of total deaths were assigned to snakebites amounting to 40,900 to 50,000 annual deaths.19,20 It occur mostly in rural areas, and more commonly among males than females and peaking at ages of 15-29. Besides Andhra Pradesh, Madhya Pradesh, Odisha is having highest Snake bite death rates (5.6/1,00,000) population.21-24 It is estimated that in Odisha 2200 cases die every year are due to snake bites. Haemotoxic snakebites are common in Odisha. Coagulopathy is the most common manifestation in cases of haemotoxic snakebites like Russell’s viper, saw scaled viper and pit vipers and its abnormality can be detected by blood coagulation tests.9,12,14,16,17 The most common causes of deaths due to haemotoxic snake bite are bleeding
due to coagulopathy and coagulopathy can also contribute to acute kidney injury (AKI).

The most common coagulopathy associated with snake envenoming worldwide is venom-induced consumption coagulopathy (VICC), which results from activation of the coagulation pathway by snake toxins including thrombin-like enzymes, prothrombin activators, and factor X activators.1,2,3

VICC has been often linked to disseminated intravascular coagulation (DIC) because of the elevated D-dimer, prolonged prothrombin time and low fibrinogen.2,4,5 However, VICC is not characterised by the other important features of DIC, such as evidence of systemic microthrombi and end organ failure.10,14 In addition the time course of VICC differs from DIC with rapid onset of coagulopathy within hours of snakebite and the resolution over 24 to 48 hours. VICC can either resolve spontaneously, which has been reported in Australian snake envenoming and also from Orissa or after antivenom therapy over 24 to 48 hours.2,4,9 DIC is mediated by activated tissue factor/factor VIIa pathway, which is not balanced by physiological anticoagulant system due to impairment in the major anticoagulant pathways.5,7,27,28,35,36 In contrast, the initiation of coagulation activation in VICC is usually due to the action of snake procoagulant toxin at one point in the coagulation pathway and not via tissue factor/factor VIIa pathway.29-31

In a proportion of patients with VICC, a clinical syndrome consistent with thrombotic microangiopathy (TMA) has been reported and is characterised by acute renal failure, thrombocytopenia, and microangiopathic haemolytic anemia.3,8,31 Coagulopathy occurs early and resolves over 48 hours (consistent with VICC) while the abnormalities consistent with TMA (platelets, hemoglobin, and renal function) remain over long period suggesting a distinct but related process. The existence of overlapping clinical syndromes of VICC and TMA in snake envenoming is the likely reason for the mistaken idea that snake bite causes DIC. But previous studies from Orissa were also found DIC was the predominant coagulation abnormality in haemotoxic snake bite.2 But newer diagnostic criteria for diagnosing DIC was not used.

Diagnosis of DIC has changed with time and newer diagnostic criteria using scoring system has been approved International society on thrombosis and hemostasis (ISTH) which were not used in previous studies from India.10,15,16,49 Presence of TMA has not been evaluated in Indian haemotoxic snake bite which is uncommon in Odisha but seen in Sri Lanka.

Therefore there is need to look into the type of venom induce coagulopathy following haemotoxic snake bite in Odisha, keeping in view due to the possibility of DIC or TMA in haemotoxic snake envenomation the present study has been undertaken from Odisha with the following aims and objectives.

Objectives

Objectives of the research were to study the type of coagulation disorder in haemotoxic snakebite envenomation and to study effect of ASV on coagulation disorder.

METHODS

Study design

This study was a facility-based observational study.

Study population

Fifty four patients admitted with history of haemotoxic snake bite with abnormal 20 min whole blood clotting test and compatible physical findings were taken for the study. This prospective observational study done from January 2017 to January 2018 in the department of medicine, SCB Medical College, Cuttack, India.

Inclusion criteria

Patients with history of snake bite with signs and symptoms compatible with envenomation like local swelling, bleeding manifestations, 20 min whole blood clotting test abnormal and age >15 years were included.

Exclusion criteria

Patients with pre-existing coagulopathy, on anti-coagulants and anti-platelet drugs, with pre renal disease and chronic liver disease. Patients with risk factors like diabetes, hypertension, connective tissue diseases, chronic infection, malignancy and patients who doesn’t give consent for participation were excluded.

Methodology

All the issues including ethical issues pertaining to the study was evaluated by the institutional review board and clearance for the same was obtained for the study.

Informed consent taken in all cases. All the clinical features are recorded in a proforma attached within. Diagnosis of DIC is done using ISTH Scoring system.10,49

The study population was divided into two groups based on DIC scoring system group A (DIC group) and group B (DIC not confirmed) for descriptive analysis.49

Investigations include 20 min whole blood clotting time, complete blood count (CBC), peripheral smear (schistocytes), liver function tests, urea, creatinine, urine microscopy, stool routine and for occult blood.10,13 Global coagulation tests like platelet count, fibrinogen degradation product (FDP), fibrinogen, prothrombin time and activated partial thromboplastin time (aPTT).
**Statistical analysis**

Quantitative variables were compared using unpaired t-tests between two groups. Qualitative variables are compared using Chi-square test. Pearson correlation was used to determine the association between two variables, p value <0.05 was considered statistically significant. The data was entered in Microsoft excel spreadsheet and analysis was done using statistical package for social sciences (SPSS) version 25.

**RESULTS**

Out of total 54 cases 23 (42.6%) cases were confirmed to be having DIC (DIC score ≥5) and 31 (57.4%) cases were not confirmed to be having DIC (DIC score <5) majority of these cases had a score of 3 (31.48%) followed by score of 1 (18.5%) (Table 1).

**Table 1: Distribution of cases according to DIC score (N=54).**

| DIC score | Number (%) | Total |
|-----------|------------|-------|
| <5        | 10 (18.5)  |       |
| 2         | 3 (5.6)    | 31 (57.4%) |
| 3         | 17 (31.48) |       |
| 4         | 1 (1.8)    |       |
| ≥5        | 15 (27.8)  |       |
| 6         | 6 (14.8)   | 23 (42.6) |
| 7 and 8   | 0          |       |

Bleeding diathesis, oliguria, shock and hepatic dysfunction were found statistically significant higher in DIC group (group A) when compared to group B except fang mark which is more commonly found in group B (Table 2).

The commonest type of bleeding was bleed at site of bite (18.5%) followed by gum bleed (12.9%) and hematuria (9.3%) (Table 3).

Patients with DIC score ≥5 the delay in ASV administration was significantly higher (46.3±28.5 hours) in comparison to patients with DIC score <5 (13.5±11.1 hours). 61.3% cases in group B have arrived to hospital in <12 hours whereas 73.9% cases in DIC group arrived after >24 hours (Table 4).

In cases with score <5 none of them progressed to frank DIC after receiving ASV for 48 hours. Majority of these cases remained stable and even in few cases complete recovery is seen. In cases who already presented with DIC at the time of hospitalization (score 5 and 6), majority of these cases remained as DIC even after 48 hours of receiving ASV even though few cases showed recovery which was not complete and 2 cases progressed to higher scores (Table 5).

10 vials of ASV found sufficient in most (87.1%) of the cases where DIC not evolved. Those presented with DIC required 21-30 vials in 56.5% cases and even 31-40 vials in 21.7% cases. Mean ASV requirement in DIC group is significantly higher than in those DIC is not confirmed (Table 6).

**Table 2: Comparison of clinical manifestations between group A (confirmed DIC) and group B (DIC not confirmed DIC score <5).**

| Parameter                  | Group A DIC (n=23) (%) | Group B coagulopathy (n=31) (DIC not confirmed) (%) | P value |
|----------------------------|------------------------|-----------------------------------------------------|---------|
| Age                        | 43.48±16.1             | 37.4±18.62                                          | 0.214   |
| Anemia (Hb<10 g%)          | 5 (21.7)               | 4 (12.9)                                            | 0.388   |
| Local cellulitis           | 23 (100)               | 31 (100)                                            | 0       |
| Bleeding manifestation     | 21 (91)                | 5 (16.1)                                            | 0.019   |
| Fang mark                  | 9 (39)                 | 22 (71)                                             | 0.00015 |
| Oliguria                   | 14 (60.9)              | 2 (6.5)                                             | 0.00001 |
| Shock                      | 12 (52.2)              | 0                                                   | 0.00003 |
| Hepatic dysfunction        | 14 (60.9)              | 1 (3.2)                                             | 0.176   |
| Gangrene                   | 2 (8.7)                | 0                                                   | 0.568   |
| Hematuria                  | 2 (8.9)                | 1 (3.2)                                             |         |

**Table 3: Comparison of bleeding manifestations between group A (confirmed DIC, score ≥5) and group B coagulopathy (DIC not confirmed DIC score <5).**

| Type of bleeding           | Group A (n=23) % (confirmed DIC, score ≥5) | Group B (n=31) coagulopathy (DIC not confirmed, score<5 ) % | Total % |
|----------------------------|---------------------------------------------|--------------------------------------------------------------|---------|
| Bleed at site of bite      | 7 (30.4)                                    | 3 (9.6)                                                    | 10 (18.5)|
| Gum bleed                  | 6 (26.1)                                    | 1 (3.2)                                                    | 7 (12.9) |
The study included a total 54 cases with haemotoxic snake bite. Out of total 54 cases (Table 1) 23 (42.6%) cases were confirmed to be having DIC (DIC score ≥5) and 31 (57.4%) cases were not confirmed to be having DIC (DIC score<5) majority of these cases had a score of 3 (31.48%) followed by score of 1 (18.5%). Majority of were in age group of 20-39 years (57.7%). Males (81.5%) were more prone to the bites with a male to female ratio of 4.4:1. Most common site of bite was in the lower extremity (85.1%). Maximum number of bites occurred between 12 noon to midnight (69.4%), most of the bites were encountered in cultivation field (61.1%). Local swelling was the commonest manifestation in both groups while bleeding including local and systemic (gum bleed 26.1%, hematuria 17.4%, oliguria (60.9%), shock (52.2%), hepatic dysfunction (60.9%) were significantly higher (p<0.05) in DIC group compared to group B (Table 2). The commonest type of bleeding was bleed at site of bite (18.5%) followed by gum bleed (12.9%) and hematuria (9.3%) (Table 3). Patients with DIC score ≥5 the delay in ASV administration was significantly higher (46.3±28.5 hours) in comparison to patients with DIC score <5 (13.5±11.1 hours).

| Type of bleeding | Group A (n=23) % (confirmed DIC, score ≥5) | Group B (n=31) coagulopathy (DIC not confirmed, score<5) % | Total % |
|------------------|------------------------------------------|------------------------------------------------|--------|
| Echymosis/hematoma/purpura  | 1 (4.3) | 0 (0) | 1 (1.9) |
| Hematuria        | 4 (17.4) | 1 (3.2) | 5 (9.3) |
| Hemoptysis       | 3 (13) | 0 (0) | 3 (13) |
| ICH              | 0 (0) | 0 (0) | 0 (0) |
| No bleeding      | 2 (8.7) | 26 (83.9) | 28 (51.9) |
| Total            | 23 | 31 | 54 (100) |

Table 4: Distribution according to duration between time of bite and hospitalization (in hours).

| Duration between time of bite and hospitalization (in hours) | Score1 | Score 2 | Score 3 | Score 4 | Score ≥5 | Total % |
|-------------------------------------------------------------|--------|---------|---------|---------|----------|--------|
| ≤12                                                         | 5 (50) | 2 (66.7) | 12 (70.6) | 0 (0) | 0 | 19 (35.2) |
| >12-24                                                      | 4 (40) | 1 (33.3) | 3 (17.6)  | 0 (0) | 6 (26.1) | 14 (25.9) |
| >24                                                        | 1 (10) | 0 (0)   | 2 (11.8)  | 1 (100) | 17 (73.9) | 21 (38.9) |
| Total                                                       | 10     | 3       | 17      | 1       | 23       | 54 (100) |

Table 5: Evolution of DIC score in snake bite cases with time after administration of ASV.

| DIC score | Day 1 (No %) | Day 3 (No %) | Stable (%) | Decreased (%) | Increased but <5 (%) | Increased ≥5 (%) |
|-----------|--------------|--------------|------------|---------------|----------------------|----------------|
| 1         | 10           | 6 (60)       | 2 (20)     | 2 (20)        | 0                    | 0 |
| 2         | 3            | 1 (33.3)     | 1 (33.3)   | 1 (33.3)      | 0                    | 0 |
| 3         | 17           | 10 (58.8)    | 1 (5.9)    | 6 (35.3)      | 0                    | 0 |
| 4         | 1            | 1 (100)      | 0          | 0             | 0                    | 0 |
| 5         | 15           | 12 (80)      | 1 (6.7)    | 0             | 2 (13.3)             | 0 |
| 6         | 8            | 5 (62.5)     | 3 (37.5)   | 0             | 0                    | 0 |
| Total     | 54           | 35 (64.8)    | 8 (14.8)   | 9 (16.6)      | 2 (3.7)              | 0 |

Table 6: Comparison of ASV requirement between group A and group B.

| ASV range (vials) | Group A (n=23) % (DIC confirmed score≥5) | Group B (n=31) coagulopathy (DIC not confirmed score<5) % |
|------------------|------------------------------------------|------------------------------------------------|--------|
| 1-10             | 0                                        | 27 (87.1) |
| 11-20            | 5 (21.7)                                 | 4 (12.9) |
| 21-30            | 13 (56.5)                                | 0       |
| 31-40            | 5 (21.7)                                 | 0       |
| Mean±SD          | 28.3±6.14 (p value <0.0001)              | 11.13±3.1 (p value <0.0001)          |

The study included a total 54 cases with haemotoxic snake bite. Out of total 54 cases (Table 1) 23 (42.6%) cases were confirmed to be having DIC (DIC score ≥5) and 31 (57.4%) cases were not confirmed to be having DIC (DIC score<5) majority of these cases had a score of 3 (31.48%) followed by score of 1 (18.5%). Majority of were in age group of 20-39 years (57.7%). Males (81.5%) were more prone to the bites with a male to female ratio of 4.4:1. Most common site of bite was in the lower extremity (85.1%). Maximum number of bites occurred between 12 noon to midnight (69.4%), most of the bites were encountered in cultivation field (61.1%). Local swelling was the commonest manifestation in both groups while bleeding including local and systemic (gum bleed 26.1%, hematuria 17.4%, oliguria (60.9%), shock (52.2%), hepatic dysfunction (60.9%) were significantly higher (p<0.05) in DIC group compared to group B (Table 2). The commonest type of bleeding was bleed at site of bite (18.5%) followed by gum bleed (12.9%) and hematuria (9.3%) (Table 3). Patients with DIC score ≥5 the delay in ASV administration was significantly higher (46.3±28.5 hours) in comparison to patients with DIC score <5 (13.5±11.1 hours).
when compared to group B (13.5±11.1 hours, p<0.05). 61.3% cases in group B had arrived to hospital in <12 hours whereas 73.9% cases in DIC group arrived after >24 hours (Table 5). In cases with score <5 none of them progressed to frank DIC after receiving ASV for 48 hours. Majority of these cases remained stable and even in few cases complete recovery is seen. In cases who already presented with DIC at the time of hospitalization (score 5 and 6), majority of these cases remained as DIC even after 48hrs of receiving ASV even though few cases showed recovery which was not complete and 2 cases progressed to higher scores.

Mean ASV requirement in DIC group was significantly higher (28.3±14) than in those DIC is not confirmed (11.13±3.1, p<0.05) (Table 6). Out of 31 cases in group B commonest abnormalities seen were low fibrinogen in 74.2% cases followed by elevated FDP 61.3%, low TPC 54.8%, INR 19.4%, proeng PT 16.1% and dPTT in 13% cases. Blood film for schistocytes were absent. 21.7% cases in DIC group had k?digo stage III AKI compared to 3.3% cases of group B. 13% cases of DIC group required hemodialysis when compared to 3.2% cases of group B.

**DISCUSSION**

The maximum number of patients were in the age group 20-39 years they constituted 57.4% patients, which is comparable to that of Sawai et al 71%. The incidence of snake bite was more common in males (81.5%) compared to females (18.5%) with a male to female ratio of 4.4:1 which may be because predominantly males were involved in outdoor activities. Most common site of snake bite was lower extremity (85.1%). Overall maximum bites occurred between 12 pm to 12 am, in our study the commonest manifestation was local swelling (100%) followed by fang mark (57.4%), bleeding (48%), oliguria (29.6%), icterus (27.7%), shock (22.2%) and gangrene (3.7%). Similar observations were made by Harshavardhana et al and Shubhamagarwal et al. For the convenience of description and analysis the study population was divided into two groups based on DIC scoring system, group A (DIC group)-23 patients with DIC score ≥5 (5-8), group B (DIC not confirmed) - 31 patients with DIC score <5 (1-4). In cases with score <5 none of them progressed to frank DIC after receiving ASV. Majority of these cases remained stable and even in few cases complete recovery is seen. In cases who already presented with DIC at the time of hospitalization (score 5 and 6). Majority of these cases remained as DIC even after 48 hours of receiving ASV. Even though few cases showed recovery which is not complete and 2 cases progressed to higher scores. Thrombocytopenia and low mean TPC were significant in group A (p<0.001) and (p=0.007) respectively. Significantly prolonged (p<0.05) PT (87%), aPTT (73.9%), INR (82.6%), elevated FDP (100%), low fibrinogen levels (87%) on the day of admission seen in group A when compared to group B. Similar observations were seen in study by Harshavardhan et al and Shubhamagarwal et al. They also concluded that first line of coagulation markers (PT, aPTT, fibrinogen) should be evaluated early to identify the coagulopathy. There was significantly high incidence of stage III AKI in DIC group (p=0.03) compared to stage I and II AKI (p=0.7). Mean creatinine levels significantly higher in DIC group (2.3±1.3) than group B (1.5±1.04) p=0.016. Contributing factors are DIC, direct nephrotoxicity, shock, intravascular haemolysis (Chugh et al). Even though 3 cases in our study had normal coagulation profile with only 1 case consistent with thrombocytopenia and normal clotting was seen raising the possibility of TMA but blood film for schistocytes were absent in all 3 cases. It was found that the coagulation parameters (PT, aPTT, thrombocytopenia, elevated FDP and low fibrinogen) DIC group remained abnormal up to day 7 even after receiving ASV. Similar observation were made by Choi in which they founded that the period of extended PT averaged 6.17±4.3 days and it continued to 7.61±4.08 days after poisonous snake bite. The period of consistency of thrombocytopenia was about 6-7 days. ADAMTS13 levels could not be evaluated in suspected TMA cases but direct coombs test was negative.

**CONCLUSION**

Coagulopathy was the most common haematological complication in haemotoxic snakebite. Though the root cause of coagulopathy was said to be Disseminated intravascular coagulation, in our study only 42.6% cases were confirmed to be having DIC whereas in remaining non DIC cases as anti-venom was administered early (<12 hours) the coagulopathy immediately appeared to be stopped, the DIC process to evolve fully was interrupted resulting in not progressing to have full features of DIC. So these case were appeared to be DIC in evolution. TMA was not found in this study. We therefore emphasise the importance of early hospitalisation (preferably <12 hours and not >24 hours), early ASV administration to prevent full blown DIC and more serious complications and also for early recovery. Further studies are needed to ascertain the exact cause of coagulopathy in non DIC group. DIC scoring system can be used to recognise patients at risk of developing serious complications.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Snakebite Mortality in India: A Nationally Representative Mortality Survey. Available at: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001018. Accessed on 16 March 2021.
2. Mohapatra BN, Nayak K, Rath RN. Coagulation disorder following viper bite in Orissa. J Indian Med Assoc. 1992;90(1):12-4.
3. Isbister GK. Snakebite doesn’t cause disseminated intravascular coagulation: coagulopathy and
thrombotic microangiopathy in snake envenoming. Semin Thromb Hemost. 2010;36(4):444-51.
4. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007;35(9):2191-5.
5. Isbister GK. Procoagulant snake toxins: laboratory studies, diagnosis, and understanding snakebite coagulopathy. Semin Thromb Hemost. 2009;35(1):93-103.
6. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004;124(5):567-76.
7. Tissue factor in infection and severe inflammation. Available at: https://pubmed.ncbi.nlm.nih.gov/16479460/. Accessed on 16 March 2021.
8. Isbister GK, Little M, Cull G, McCoubrie D, Lawton P, Szabo F, et al. Thrombotic microangiopathy from Australian brown snake (Pseudonaja) envenoming. Intern Med J. 2007;37(8):523-8.
9. Agarwal S. Haematological and Coagulation Profile in Snake Envenoming. J Clin Biomed Sci. 2014;4(4):361-4.
10. DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis, Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thrombosis J. 2016;14(1):42.
11. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323-35.
12. WHO | Guidelines for the management of snakebites, 2nd edition. WHO. World Health Organization; Available at: http://www.who.int/snakebites/resources/9789290225300/en/. Accessed on 16 March 2021.
13. Management of Snake Bite, Ministry of Health and Family Welfare, Govt of India, jan 2016. - Google Search. Available at: https://www.google.com/search?q=13.+Management+of+Snake+Bite%2C+Ministry+of+Health+and+Family+Welfare%2C+Govt+of+India+jan+2016.&rlz=1C1YTUH_enIN933IN933&sourceid=chrome&ie=UTF-8. Accessed on 16 March 2021.
14. Kim JS, Yang JW, Kim MS, Han ST, Kim BR, Shin MS, et al. Coagulopathy in patients who experience snakebite. Korean J Intern Med. 2008;23(2):94-9.
15. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327-30.
16. Snakebite envenoming. Available at: https://www.who.int/westernpacific/health-topics/snakebite. Accessed on 16 March 2021.
17. Disorders Caused by Venomous Snakebites and Marine Animal Exposures | Harrison’s Principles of Internal Medicine, 19e | AccessPharmacy | McGraw-Hill Medical. Available at: https://accesspharmacy.mhmedical.com/content.aspx?bookid=1130&sectionid=79757620. Accessed on 16 March 2021.
18. Warrell DA, Gutiérrez JM, Calvete JJ, Williams D. New approaches & technologies of venomics to meet the challenge of human envenoming by snakebites in India. Indian J Med Res. 2013;138(1):38-59.
19. Snakebites under-reported in India. Nature India. Available at: https://www.natureasia.com/en/nindia/article/10.1038/nindia.2012.69. Accessed on 16 March 2021.
20. Govt of India, Central Bureau of health Intelligence. Health status Indicators, National Health profile 2007&2008;(Provisional):3.1.2.9 state/UT wise cases and Deaths Due to snakebite in India. 107-108 Available at: http://ebhidghs.nic.in/writereaddata/mainlink File/ Health status Indicators.pdf. Accessed on 16 March 2021.
21. State/UT Wise cases and Deaths due to snakebite in India 2010 (Provisional). Entry no:3.15 Health status indicators 2010. Central Bureau of Health intelligence. 2010.
22. Kasturiratne A, Wickremasinghe AR, Silva N de, Gunawardena NK, Pathmeswaran A, Premaratna R, et al. The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths. Plos Med. 2008;5(11):218.
23. Hati AK, Mandal M, De MK, Mukherjee H, Hati RN. Epidemiology of snake bite in the district of Burdwan, West Bengal. J Indian Med Assoc. 1992;90(6):145-7.
24. Snake venom poisoning: experience with 633 cases. Available at: https://pubmed.ncbi.nlm.nih.gov/7875785/. Accessed on 16 March 2021.
25. Kumaratne SAM. Common Kraits (Bangarus.caeruleus) bite in Anuradhapura; srilanka-A Prospective clinical study. Postgrad Med J. 2002;78:276-86.
26. Anthonypillai CN, Wass JAH, Warrell DA, Rajaratnam HN. Hypopituitarism following envenoming by Russell’s vipers (Daboia siamensis and D. russelli) resembling Sheehan’s syndrome: first case report from Sri Lanka, a review of the literature and recommendations for endocrine management. QJM. 2011;104(2):97-108.
27. McDonald B, Davis RP, Kim S-J, Tse M, Esmon CT, Kolaczkowska E, et al. Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice. Blood. 2017;129(10):1357-67.
28. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93(1):327-58.
29. Østerud B, Bjørklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27(6):605-17.
30. Esmon C. Esmon, C.T. Role of coagulation inhibitors in inflammation. Thromb Haemost. 2001;86:51-6.
31. Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost. 2016;115(4):712-28.
32. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2:16037.
33. Boral BM, Williams DJ, Boral I. Disseminated Intravascular Coagulation. Am J Clin Pathol. 2016;146(6):670-80.
34. Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. Intern Emerg Med. 2013;8(1):23-32.
35. Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, et al. Hematology: Basic Principles and Practice. Elsevier Inc. 2017.
36. Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018;131(8):845-54.
37. Sawai Y, Hunma M. Snake bites in India Snake. 1975;7:1-16.
38. Harshavardhan. Snake bite induced coagulopathy clinical profile and prediction of poor outcome. Int J Sci Stud. 2014;2(1):2-5.
39. Shubhamagarwal. Haematological and coagulation profile in Snake Envenomation. J Clin Biomed Sci. 2014;(4):361-4.
40. Chugh KS. Snake-bite-induced acute renal failure in India. Kidney Int. 1989;35(3):891-907.
41. Kim JS, Yang JW, Kim MS, Han ST, Kim BR, Shin MS, et al. Coagulopathy in patients who experience snakebite. Korean J Intern Med. 2008;23(2):94-9.